Watchlist Price Alert

Akoya Biosciences Inc. (AKYA)

NASDAQ: AKYA · Real-Time Price · USD

1.03

-0.13 (-11.21%)

At close: May 13, 2025, 3:59 PM

1.00

-2.91%

After-hours: May 13, 2025, 04:16 PM EDT

-11.21% (1D)

Bid	0.82
Market Cap	51.37M
Revenue (ttm)	81.67M
Net Income (ttm)	-55.37M
EPS (ttm)	-1.12
PE Ratio (ttm)	-0.92
Forward PE	-2.13
Analyst	Hold

Ask	1.02
Volume	403,552
Avg. Volume (20D)	244,293
Open	1.15
Previous Close	1.16
Day's Range	0.98 - 1.16
52-Week Range	0.98 - 4.65
Beta	1.35

About AKYA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AKYA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AKYA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Akoya Biosciences has released their quartely earnings on May 12, 2025:

Revenue of $16.64M misses estimates by $3.55M, with -9.32% YoY decline.

EPS of -0.32 misses estimates by -0.14, with 33.33% YoY growth.

Why Price Moved

6 months ago

-23%

Akoya Biosciences shares are trading lower after t... Unlock content with Pro Subscription

6 months ago

-2.49%

Akoya Biosciences shares are trading lower after the company reported worse-than-expected Q3 financial results.

News

1 day ago · zacks.com

Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago.

6 days ago · businesswire.com

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Bioscience...

1 week ago · zacks.com

Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · businesswire.com

Quanterix and Akoya Biosciences Announce Amended Merger Agreement

BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences ...

4 weeks ago · businesswire.com

Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences

CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (“Quanterix”...

1 month ago · businesswire.com

Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya

RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of approximately 7.5% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: ...

1 month ago · businesswire.com

Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences

1 month ago · zacks.com

Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago.

1 month ago · businesswire.com

Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call

RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of 7.47% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Kent L...

2 months ago · businesswire.com

Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences

RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today hig...